Archives

  • 2018-07
  • 2018-10
  • 2018-11
  • 2019-04
  • 2019-05
  • 2019-06
  • 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2019-12
  • 2020-01
  • 2020-02
  • 2020-03
  • 2020-04
  • 2020-05
  • 2020-06
  • 2020-07
  • 2020-08
  • 2020-09
  • 2020-10
  • 2020-11
  • 2020-12
  • 2021-01
  • 2021-02
  • 2021-03
  • 2021-04
  • 2021-05
  • 2021-06
  • 2021-07
  • 2021-08
  • 2021-09
  • 2021-10
  • 2021-11
  • 2021-12
  • 2022-01
  • 2022-02
  • 2022-03
  • 2022-04
  • 2022-05
  • 2022-06
  • 2022-07
  • 2022-08
  • 2022-09
  • 2022-10
  • 2022-11
  • 2022-12
  • 2023-01
  • 2023-02
  • 2023-03
  • 2023-04
  • 2023-05
  • 2023-06
  • 2023-07
  • 2023-08
  • 2023-09
  • 2023-10
  • 2023-11
  • 2023-12
  • 2024-01
  • 2024-02
  • 2024-03
  • 2024-04
  • AP activation is known to upregulate

    2023-12-01

    AP-1 activation is known to upregulate downstream target genes including MK-4827 Racemate D1, c-myc, Bcl-xl, MMP-9, EGFR, and specific miRNAs that are involved in progression and metastasis of tumors. Moreover, matrix metalloproteinase-2 has been shown as a downstream gene of AP-1, triggered by 15-HETE in the regulation of angiogenesis [19]. Furthermore, it has been reported that AP-1 signaling increased the expression of COX-2 and iNOS in mouse skin [24]. In the present study, we have confirmed that both hypoxia and 15-HETE induce cyclin D1 expression in an AP-1 dependent manner. In addition, we observed that the activation of AP-1 affects the expression of both 15-LOX1 and 15-LOX2, suggesting a reciprocal regulation between 15-LOX and AP-1. However, whether AP-1 directly binds to 15-LOX promoter or acts through other signaling pathways needs to be elucidated by further studies. Thus, these findings indicate that, in addition to the known downstream genes, 15-LOX is also a target of AP-1, and the reciprocal regulation between 15-LOX and AP-1 is involved in hypoxia-induced proliferation in PASMCs.
    Introduction Olmsted syndrome (OS; Online Mendelian Inheritance in Man (OMIM) #614594) is a severe keratinization disorder characterized by the combination of palmoplantar and periorificial keratoderma and is often associated with hypotrichosis and intense itching [1]. OS is a very rare congenital disorder, and only 73 cases have been reported so far [1]. Most of the reported OS cases were sporadic; however, some familial cases with different hereditary patterns were also found. The hereditary patterns were either autosomal or X-linked and either dominant or recessive [1]. TRPV3 (transient receptor potential vanilloid subtype 3) on chromosome 17 and MBTPS2 (membrane-bound transcription factor protease, site 2) on chromosome X have been identified as the causative genes of OS [2], [3]. TRPV3 is a thermosensitive Ca2+ channel [4], [5], [6]. Most of the TRPV3 mutations (p.Gly573Ser, p.Gly573Cys, p.Gly573Ala, p.Gln580Pro, p.Leu673Phe, p.Trp692Gly, and p.Trp692Cys) found in OS patients were dominant [1], and expression of the mutant proteins caused increases in intracellular Ca2+ concentrations [2], [7]. Recessive mutations in TRPV3 have also been identified for OS [1], [8]. The reason why these diverse inheritance patterns exist for OS is currently unclear. The MBTPS2 mutations found in OS patients were recessive [3], [9]. MBTPS2 is a component of the regulated intramembrane proteolysis machinery that regulates cholesterol homeostasis and the unfolded protein response by cleaving membrane-spanning regulatory proteins [10]. TRPV3 belongs to the vanilloid family of transient receptor cation channels [11]. TRPV3 was shown to be highly expressed in skin, primarily in hair follicles and in keratinocytes that are present in the basal layer of MK-4827 Racemate the epidermis, and its expression has also been detected in brain, spinal cord, and dorsal root ganglion [5], [6]. TRPV3 is activated by temperature, with a threshold of 31–39°C [4], [5], [6], as well as by ligands such as 2-aminoethoxydiphenyl borate and farnesyl pyrophosphate, which is an intermediate metabolite of the mevalonate pathway [12], [13]. Furthermore, arachidonic acid and other unsaturated fatty acids were reported to potentiate TRPV3 activity [14], while the pro-resolving lipid mediator 17(R)-resolvin D1 was found to inhibit TRPV3 activity [15]. Thus, there appears to be a relationship between TRPV3 activity and lipids. WBN/Kob-Ht rats (hereafter called Ht rats) and DS-Nh mice were selected as spontaneous hairless rodent strains, and both strains had dominant Trpv3 mutations (p.Gly573Cys in Ht rats and p.Gly573Ser in DS-Nh mice), the same as two of the mutations found in OS patients [16]. These rodents developed dermatitis accompanied with hyperkeratosis and acanthosis under conventional conditions [17], [18]. The p.Gly573Ser transgenic mice also showed dermatitis with severe itching and defects in hair growth [19]. However, OS-like phenotypes were not observed in Trpv3 knockout mice; rather, they exhibited thin stratum corneum, wavy whiskers, and misaligned hair follicles [20], [21]. These results suggest that OS is caused by gain-of-function of TRPV3.